TABLE 4.
ROR025 values between class‐specific ICIs monotherapy/polytherapy (with chemotherapy) and the top 10 most frequently reported renal AEs in FAERS database
| PT | Nivo | Pemb | Atez | Avel | Durv | Ipil | Poly2 |
|---|---|---|---|---|---|---|---|
| Acute kidney injury | 3.68 | 1.31 | 2.69 | 0.94 | 0.95 | 1.08 | 6.62 |
| Renal failure | 0.14 | 0.41 | 0.49 | 0.50 | 1.44 | ||
| Renal impairment | 0.20 | 0.91 | 0.78 | ||||
| Urinary tract infection | 0.50 | 1.63 | 0.36 | ||||
| Tubulointerstitial nephritis | 2.38 | ||||||
| Chronic kidney disease | 0.10 | ||||||
| Nephritis | 2.71 |
In the table, nivo, pemb, cemi, atez, avel, durv, ipil, poly1, poly2, and poly3, represent nivolumab, pembrolizumab, cemiplimab, atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab+ipilimumab+ pembrolizumab, nivolumab+ipilimumab, and ipilimumab+pembrolizumab, respectively. Bold values indicate the signals with statistical significance.